Vaccine Scheduler

Meningococcal Disease: Recommended vaccinations

	General recommendation
	Recommendation for specific groups only
	Catch-up (e.g. if previous doses missed)
	Vaccination not funded by the National Health system
	Mandatory vaccination

	Weeks	Months												Years
	6	2	3	4	5	6	10	11	12	13	14	15	23	2	10	11	12	13	14	15	16	17	18	19	24	≥ 25
Austria		MenB¹	MenB						MCV4/MenB						MCV4

Belgium												MCV4							MCV4²

Bulgaria	MCV4³	MenB⁴	MCV4³	MenB⁴

Croatia		MCV4/MenB⁵

Cyprus									MCV4					MPSV4⁶

Czechia		MenB⁷		MenB⁷					MCV4/MenB⁷										MCV4/MenB⁷				MCV4/MenB⁷

Denmark

Estonia

Finland	MCV4/MenB⁸													MCV4/MenB⁹

France			MenB¹⁰		MenB	MCV4¹¹			MCV4/MenB							MCV4¹²				MCV4/MenB

Germany		MenB¹³		MenB¹³					MenB¹³								MCV4¹³			MCV4¹³

Greece		MenB		MenB			MenC¹⁴		MenB							MCV4		MCV4					MCV4/MenB

Hungary		MenC		MenC								MenC¹⁵

Iceland									MCV4

Ireland		MenB		MenB					MenB	MenC							MCV4

Italy			MenB¹⁶		MenB¹⁶				MCV4			MenB¹⁶		MenB¹⁶			MCV4¹⁷

Latvia

Liechtenstein														MCV4¹⁸		MCV4¹⁹

Lithuania			MenB		MenB				MenB²⁰

Luxembourg			MenB		MenB				MenB	MCV4										MCV4²¹			MCV4²²

Malta		MenB	MCV4	MenB					MenB	MCV4									MCV4

Netherlands											MCV4²³								MCV4²³

Norway

Poland		MCV4/MenB²⁴

Portugal		MenB		MenB					MCV4/MenB

Romania

Slovakia

Slovenia

Spain		MenB²⁵		MenB - MenC²⁵					MenB - MenC²⁵								MCV4²⁶	MCV4²⁷

Sweden

Footnotes:

MenB vaccination is recommended as early as possible from the age of 2 months and not funded. Catch-up vaccinations are recommended up to the age of 25. MenACWY vaccination is recommended as early as possible at the age of 13 months and not funded. One dose of the tetravalent conjugated meningococcal vaccine is recommended between the ages of 10-13 and funded. Additionally, please refer to official recommendations for timing and number of doses required according to age: https://www.sozialministerium.gv.at/impfplan (p. 77ff)
Adolescent dose recommended but not implemented in free vaccination programs
Two doses are recommended for infants aged 6 weeks to 6 months (first dose at 6 weeks of age, second dose 2 months later). In infants over 6 months of age, adolescents and adults, one dose should be administered. https://plusmen.bg/bg/optional/meningitidis
A two-dose regimen with an interval between doses of 2 months (in children up to 2 years of age) and 1 month (in children over 2 years of age and in adults). In children up to 2 years of age, it is necessary to administer an additional dose (reimmunization), according to the age interval indicated in the vaccine leaflet. More information: https://plusmen.bg/bg/optional/meningitidis
Vaccination is recommended and funded by Croatian Health Insurance for certain at risk groups, both MenB and MenACWY (children and adults - for example: splenectomized individuals, people after HSCTs, persons with disorders of complement components, including those receiving eculizumab or ravulizumab therapy)
vaccines only given on specific indications
MenB vaccination for infants is covered by health insurance if the schedule is started before the age of 1 year, and vaccination for adolescents if vaccination is started at the age interval from 14 to 16 years. MCV4 vaccination for toodlers is covered by health insurance if is administered at the age interval from 12 to 23 months and vaccination for adolescents if vaccination is started at the age interval from 14 to 16 years. Vaccination with MenB and MCV4 vaccines is covered by health insurance for persons of all ages with immune disorders. More details of the recommendation is available at: https://www.vakcinace.eu/doporuceni-a-stanoviska/doporuceni-ceske-vakcinologicke-spolecnosti-cls-jep-pro-ockovani-proti-invazivnim-meningokokovym-2
The meningococcal ACWY vaccine and the meningococcal B vaccine are provided free of charge as part of the national vaccination programme to persons who are at increased risk of severe meningococcal infection because of an underlying medical condition or medication: complement deficiency, treatment with complement-inhibiting medication, asplenia, hyposplenia (reduced spleen function), including sickle cell disease, chronic graft-versus-host disease (GvHD) after stem-cell transplantation. MCV4: the vaccine (Nimenrix) can be given from 6 weeks of age. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, including booster dose timing, please refer to the official information available at: https://thl.fi/ohjeita-ammattilaisille/meningokokki-acwy-rokote#kenelle-meningokokki-acwy-rokote-annetaan MenB: The vaccine (Bexsero) can be given from 2 months of age. The vaccine is given to infants under 6 months of age as a basic series of two or three doses. For children aged six months or older, the basic series includes two doses. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, including booster dose timing, please refer to the official information available at: https://thl.fi/ohjeita-ammattilaisille/meningokokki-b-rokote#jos-tilaat-bexsero-rokotetta-huomioi-tama
MCV4: The meningococcal ACWY vaccine is provided free of charge as part of the national vaccination programme to persons who are at increased risk of severe meningococcal infection because of an underlying medical condition or medication:complement deficiency, treatment with complement-inhibiting medication, asplenia, hyposplenia (reduced spleen function), including sickle cell disease, chronic graft-versus-host disease (GvHD) after stem-cell transplantation. The vaccine (Menveo) for persons aged 2 years and older: a single dose is given for primary vaccination. If a person aged 2 years and older has previously received one dose of Nimenrix, the vaccination series is completed with one dose of Menveo. Data on the effectiveness of Menveo are limited in adults aged 56–65 years and are lacking in those aged 65 years and older; however, the vaccine may also be administered to persons aged 55 years and older. For detailed guidance, please refer to the official information available at: https://thl.fi/ohjeita-ammattilaisille/meningokokki-acwy-rokote#kenelle-meningokokki-acwy-rokote-annetaan MenB: The meningococcal B vaccine is available free of charge as part of the national vaccination programme to people who are at increased risk of developing a serious meningococcal infection due to their illness or medication: complement deficiency, treatment with complement-inhibiting medication, asplenia, hyposplenia (reduced spleen function), including sickle cell disease, chronic graft-versus-host disease (GvHD) after stem-cell transplantation. The vaccine (Bexsero) for individuals aged 2 years and older: 2 doses, at least one month apart. There is no information on the effectiveness of the vaccine in people over 50 years of age. However, the vaccine can also be given to people over the age of 50. For detailed guidance, please refer to the official information available at: https://thl.fi/ohjeita-ammattilaisille/meningokokki-b-rokote#jos-tilaat-bexsero-rokotetta-huomioi-tama
Vaccination introduced in 2022. Mandatory since January 2025.
Introduced in January 2025 in replacement of monovalent MenC
More information available at: https://www.service-public.fr/particuliers/actualites/A16520
For MenB, according to the product information, the vaccination series consists of 3 vaccine doses for children aged 2–23 months and 2 vaccine doses for children aged 24 months and older. For MenACWY, recommendation in October 2025 to vaccinate at age 12-14 years (catch-up through 24 years) and recommendation against MenC vaccination for infants and small children. https://www.rki.de/DE/Themen/Infektionskrankheiten/Impfen/Staendige-Impfkommission/Empfehlungen-der-STIKO/PM/PM_2025-10-30.html
MenC: 1 dose at the age of 10 months
Since January 1st, 2017, the meningococcal C vaccine is offered to all children aged under 2 years with 100% reimbursement on a voluntary-based approach.
Please refer to local recommendations for age of administration. MenB should not to be co-administered with other vaccinations.
Meningococcal ACWY, one dose for adolescents age 12-18
Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 5 years of age.
Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 20 years of age.
Can be administered concomitantly with MMR
Booster dose of vaccine against invasive meningococcal disease ACWY
Catch-up recommendation for those at increased risk of complications or severe disease also after the age of the general recommendation (https://sante.public.lu/dam-assets/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite/202300606-vaccination-contre-le-menincocoques-mj-2023-vf.pdf)
Also prescribed to medical high risk groups of other ages by the attending medical doctor and reimbursed by the health insurer (https://lci.rivm.nl/factsheets/meningokokken-acwy-vaccinatie)
Men B and Men ACWY vaccines recommended and refunded only in risk groups for people aged 12 months - 18 years
Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
One dose at 12 years to individuals who have not received any doses of MCV4 since 10 years of age. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
The catch-up vaccination programme for individuals aged 13 to 18 years will be introduced gradually (more information available at: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/adolescentes-meningo/home.htm